Aliases & Classifications for Mouth Disease

MalaCards integrated aliases for Mouth Disease:

Name: Mouth Disease 12 15 17
Mouth Diseases 45 74
Abnormality of the Mouth 30
Mouth Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:403
MeSH 45 D009059
NCIt 51 C27641 C3240
UMLS 74 C0026636

Summaries for Mouth Disease

MedlinePlus : 44 Your mouth is one of the most important parts of your body. It has many different functions. It allows you to Take in food and drink Breathe in air Start digestion, with your teeth chewing the food you eat and your salivary glands releasing saliva to help break down the food Speak and sing Show emotion, by smiling or pouting Any problem that affects your mouth can make it hard to eat, drink, or even smile. Some common mouth problems include Cold sores - painful sores on the lips and around the mouth, caused by a virus Canker sores - painful sores in the mouth, caused by bacteria or viruses Thrush - a yeast infection that causes white patches in your mouth Leukoplakia - white patches of excess cell growth on the cheeks, gums or tongue, common in smokers Dry mouth - a lack of enough saliva, caused by some medicines and certain diseases Gum or tooth problems Bad breath Treatment for mouth disorders varies, depending on the problem. If a mouth problem is caused by some other disease, treating that disease can help. It is also important to keep your mouth clean and healthy by brushing, flossing, and not using tobacco.

MalaCards based summary : Mouth Disease, also known as mouth diseases, is related to hand, foot and mouth disease and meningitis, and has symptoms including tinnitus, snoring and sore throat. An important gene associated with Mouth Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Metronidazole and Risedronate have been mentioned in the context of this disorder. Affiliated tissues include bone, salivary gland and eye, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A gastrointestinal system disease that is located in the mouth.

Related Diseases for Mouth Disease

Diseases related to Mouth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 207)
# Related Disease Score Top Affiliating Genes
1 hand, foot and mouth disease 34.3 HMGB1 IFNG IL10 IL17F IL6 SCARB2
2 meningitis 30.6 CRP IFNG IL10 IL6
3 influenza 30.5 DDX58 IFNA1 IFNG TLR3
4 brucellosis 30.4 CRP IFNG IL10 IL6 TLR4
5 trypanosomiasis 30.3 IFNG IL10 IL6
6 nervous system disease 30.2 CRP IFNG IL10 IL6
7 graft-versus-host disease 30.2 IFNG IL10 IL6
8 severe acute respiratory syndrome 30.1 CRP IFNA1 IFNG STAT1
9 kawasaki disease 30.1 CRP IL10 IL6
10 acute pancreatitis 30.0 CRP IL10 IL6
11 measles 29.9 DDX58 IFNA1 IFNG IL6 STAT1 TLR3
12 burning mouth syndrome 11.1
13 oral hairy leukoplakia 10.7
14 hemorrhagic fever 10.6 IFNG IL10 IL6
15 pyelitis 10.5 CRP IL6 TLR4
16 relapsing polychondritis 10.5 CRP IFNG IL6
17 central nervous system vasculitis 10.5 CRP IFNG IL6
18 coccidioidomycosis 10.5 IL10 STAT1 TLR4
19 variola major 10.5 IFNG TLR3 TLR4
20 cystic echinococcosis 10.5 IL10 IL6 TLR4
21 viral meningitis 10.5 CRP IFNG IL6
22 intermediate uveitis 10.5 IFNG IL10 IL6
23 eales disease 10.5 IFNG IL10 IL6
24 acute pyelonephritis 10.5 CRP IL10 IL6
25 scrub typhus 10.5 CRP IL10 TLR4
26 perinatal necrotizing enterocolitis 10.5 CRP IL6 TLR4
27 hematopoietic stem cell transplantation 10.5 IFNG IL10 IL6
28 cold agglutinin disease 10.5 CRP IL6
29 bacterial sepsis 10.5 CRP IL10 TLR4
30 plasmodium vivax malaria 10.5 IFNG IL10 IL6
31 lymph node disease 10.5 CRP IL10 IL6
32 spondyloarthropathy 10.5 IFNG IL10 IL6
33 cephalosporin allergy 10.5 IFNG IL10
34 bacterial pneumonia 10.5 CRP IL6 TLR4
35 pericarditis 10.5 CRP IFNG IL6
36 mixed connective tissue disease 10.5 IFNG IL10 IL6
37 temporal arteritis 10.5 CRP IFNG IL6
38 prostatitis 10.5 IL10 IL6 VDR
39 reactive arthritis 10.5 CRP IFNG IL10
40 tropical spastic paraparesis 10.5 IFNG IL10 IL6
41 autoimmune disease of musculoskeletal system 10.5 CRP IL10 IL6
42 lepromatous leprosy 10.5 IFNG IL10 VDR
43 bronchiolitis obliterans 10.5 IFNG IL10 IL6
44 rasmussen encephalitis 10.5 HMGB1 IFNG IL6
45 parasitic protozoa infectious disease 10.5 IFNG IL10 IL6
46 pneumonia 10.5 CRP IL10 IL6 TLR4
47 multicentric castleman disease 10.5 CRP IFNG IL10 IL6
48 chorioamnionitis 10.5 CRP IL6 TLR4
49 bacterial meningitis 10.5 CRP IL10 IL6
50 castleman disease 10.5 CRP IFNG IL10 IL6

Graphical network of the top 20 diseases related to Mouth Disease:



Diseases related to Mouth Disease

Symptoms & Phenotypes for Mouth Disease

UMLS symptoms related to Mouth Disease:


tinnitus, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder, halitosis, oral manifestations

GenomeRNAi Phenotypes related to Mouth Disease according to GeneCards Suite gene sharing:

27 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.47 CRP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.47 IL10
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.47 IL10
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.47 CRP
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.47 IL10
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-38 9.47 EIF4G1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.47 IL10
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.47 EIF4G1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.47 CRP EIF4G1 IL10 TLR4
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.47 CRP
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-94 9.47 EIF4G1

MGI Mouse Phenotypes related to Mouth Disease:

47 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 ATG5 BECN1 DDX58 IFNG IL10 IL17F
2 cardiovascular system MP:0005385 10.38 ATG5 BECN1 CRP IFNG IL10 IL6
3 homeostasis/metabolism MP:0005376 10.37 ATG5 BECN1 CRP DDX58 IFNG IL10
4 immune system MP:0005387 10.35 ATG5 BECN1 CRP DDX58 IFNG IL10
5 growth/size/body region MP:0005378 10.34 ATG5 BECN1 DDX58 IFNG IL10 IL17F
6 behavior/neurological MP:0005386 10.32 ATG5 BECN1 IFNG IL10 IL6 ITGAV
7 cellular MP:0005384 10.3 ATG5 BECN1 DDX58 IFNG IL10 IL6
8 digestive/alimentary MP:0005381 10.29 ATG5 DDX58 IFNG IL10 IL17F IL6
9 mortality/aging MP:0010768 10.25 ATG5 BECN1 DDX58 IFNG IL10 IL17F
10 endocrine/exocrine gland MP:0005379 10.24 ATG5 BECN1 IFNG IL10 IL6 ITGAV
11 muscle MP:0005369 10.07 ATG5 IFNG IL10 IL6 ITGAV NOTCH1
12 integument MP:0010771 10.06 BECN1 IFNG IL10 IL6 NOTCH1 STAT1
13 liver/biliary system MP:0005370 10.03 ATG5 DDX58 IFNG IL10 IL6 NOTCH1
14 nervous system MP:0003631 10.03 ATG5 BECN1 IFNG IL10 IL6 ITGAV
15 neoplasm MP:0002006 10.02 BECN1 DDX58 IFNG IL10 IL6 ITGAV
16 normal MP:0002873 9.81 ATG5 EIF4G1 IFNG IL10 IL17F NOTCH1
17 renal/urinary system MP:0005367 9.56 ATG5 IFNG IL6 ITGAV NOTCH1 SCARB2
18 respiratory system MP:0005388 9.23 ATG5 IFNG IL10 IL17F IL6 NOTCH1

Drugs & Therapeutics for Mouth Disease

Drugs for Mouth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 902)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 443-48-1 4173
2
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
3
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9004-61-9 53477741
4
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-56-1 2713 9552079
5
Pilocarpine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 54-71-7, 92-13-7 5910
6 sodium fluoride Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7681-49-4
7
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
8
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 26787-78-0 33613
9
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 329-65-7 838
10
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
11
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 564-25-0 54671203
12
Levonorgestrel Approved, Investigational Phase 4 17489-40-6, 797-63-7 13109
13
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
14
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
15
Polyestradiol phosphate Approved Phase 4 28014-46-2
16
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
17
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
18
Hexetidine Approved, Investigational Phase 4 141-94-6
19
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
20
Aminocaproic Acid Approved, Investigational Phase 4,Phase 3 60-32-2 564
21
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
22
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 103-90-2 1983
23
Nystatin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1400-61-9 11953884
24
Coal tar Approved Phase 4,Phase 3,Phase 2,Not Applicable 8007-45-2
25
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
27
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
28
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
29
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Not Applicable 67-73-2 6215
30
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
31
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 53-03-2 5865
32
Calcium Carbonate Approved, Investigational Phase 4,Not Applicable 471-34-1
33
Acyclovir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59277-89-3 2022
34
Docosanol Approved, Investigational Phase 4 30303-65-2, 661-19-8 12620
35
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
36
Triclosan Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 3380-34-5 5564
37
Pentetic acid Approved Phase 4,Phase 3,Not Applicable 67-43-6
38
Simvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 79902-63-9 54454
39
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Not Applicable 62-33-9, 60-00-4 6049
40
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091
41
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 10118-90-8 5281021
42
Azithromycin Approved Phase 4,Phase 2,Not Applicable 83905-01-5 55185 447043
43
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 85721-33-1 2764
44
Thymol Approved Phase 4,Not Applicable 89-83-8 6989
45
Methyl salicylate Approved, Vet_approved Phase 4,Not Applicable 119-36-8 4133
46
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
47
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 7440-66-6 32051
48
Cetylpyridinium Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7773-52-6
49
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-02-2 5743
50
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1177-87-3

Interventional clinical trials:

(show top 50) (show all 2977)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Cyanoacrylate Adhesive (PeriAcryl®90 HV) in Periodontal Wound Healing Unknown status NCT02826109 Phase 4
2 The Treatment of Periodontal Diseases Unknown status NCT01318928 Phase 4 Metronidazol
3 Effect of Actonel on Periodontal Health of Postmenopausal Women Unknown status NCT00594334 Phase 4 Risedronate
4 Efficacy and Safety of a Commercially Available Injectable Hyaluronic Acid Dental Filler for Periodontal Pockets Unknown status NCT02391974 Phase 4
5 Effect of Pilocarpine in Patients With Xerostomia Unknown status NCT02982577 Phase 4 Pilocarpine
6 Antiplaque Effect of Essential Oils With and Without Alcochol on an in Situ Model of Oral Biofilm Growth Unknown status NCT02946801 Phase 4 Essential oils;Essential oils without alcohol;Sterile water
7 Manually Versus Digitally Fabricated Removable Partial Dentures Unknown status NCT01191073 Phase 4
8 Metronidazole and Amoxicillin for the Treatment of Type 2 Diabetic Subjects With Periodontitis Unknown status NCT02135952 Phase 4 MTZ+AMX
9 Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy Unknown status NCT01532674 Phase 4
10 Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care Unknown status NCT01195493 Phase 4
11 Study of Scaling and Root Planing With PerioWave Versus Scaling and Root Planing Alone in Chronic Periodontitis Unknown status NCT00297531 Phase 4
12 SRP in Combination With PERIOWAVE in Comparison to SRP Alone in Chronic Periodontitis Unknown status NCT00296881 Phase 4
13 Norplant and Irregular Bleeding/Spotting Unknown status NCT00064766 Phase 4 doxycycline
14 Efficacy of Three Antibiotic Protocols for Aggressive Periodontitis Treatment Unknown status NCT02839421 Phase 4 Scaling and Root Planing combined with moxifloxacin
15 Evaluation of a Lateral Window Technique Augmentation for Maxillary Sinus Using Ultrasound Activated Pins Unknown status NCT02449707 Phase 4
16 Methodology Antiseptic Application, Influence on Oral Biofilm. Unknown status NCT02267239 Phase 4 essential oils, immersion;Chlorhexidine, immersion;essential oils, mouthwash;chlorhexidine, mouthwash
17 Randomized Trial to Evaluate the Efficacy of Two Different Toothbrushes on Plaque Control Unknown status NCT03099551 Phase 4
18 Effect of Probiotic Lozenges on Halitosis in Patients With Chronic Periodontitis Unknown status NCT02789436 Phase 4 L. reuteri Prodentis® lozenges
19 Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients Unknown status NCT02238288 Phase 4 Aminocaproic acid;lidocaine and epinephrine;Paracetamol
20 Pinhole Surgical Technique With And Without Use Of Buttons For Treatment Of Multiple Gingival Recessions: RCT Unknown status NCT02632968 Phase 4
21 Laser De-epithelialization for Epithelial Exclusion in Root Coverage Procedure: a Clinical Study Unknown status NCT02626117 Phase 4
22 Platelet Rich Fibrin in the Treatment of Palatal Wounds Unknown status NCT02438046 Phase 4
23 Oral Hygiene Regimen in Patients on HCT Unknown status NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
24 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
25 Efficacy of Different Chlorhexidine Concentrations Unknown status NCT02911766 Phase 4 Chlorhexidine 0.2% Mouthrinse;Chlorhexidine 0.12% mouthrinse;Chlorhexidine 0.06% mouthrinse
26 Adhesion of Connective Tissue Around Laser-treated Abutments for Dental Implants - Clinical Trial in Humans Unknown status NCT01954485 Phase 4
27 Anticaries Effect of Probiotic Lactobacillus Brevis CD2 (Lb CD2). Unknown status NCT01778699 Phase 4
28 Treatment of Periodontitis in Obese Individuals Unknown status NCT03103204 Phase 4
29 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
30 Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
31 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
32 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
33 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
34 Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis) Unknown status NCT00467662 Phase 4 Acyclovir 5%;Docosanol 10%
35 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
36 Effect of Xiaoer Jiebiao Oral Liquid on Hand-foot-mouth Disease Completed NCT02328651 Phase 4 Ribavirin plus Xiao'er jiebiao oral liquid;Ribavirin
37 Immunogenicity and Safety of Two Different Commercial EV71 Vaccines Completed NCT03873740 Phase 4
38 Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine Completed NCT03278132 Phase 4
39 Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines Completed NCT03274102 Phase 4
40 Regenerative Surgical Treatment of Peri-implantitis Completed NCT02500654 Phase 4
41 Melatonin as an Adjunctive Therapy for Chronic Periodontitis. Completed NCT03368430 Phase 4 Placebo
42 Clinical Investigation of the Effects of Colgate Total Toothpaste as Compared to a Matching Placebo on Periodontal Disease and Systemic Inflammatory Markers Completed NCT02670135 Phase 4 Triclosan Containing Toothpaste;Triclosan Free Toothpaste
43 Locally Delivered Doxycycline Adjunct to Nonsurgical Periodontal Therapy. Completed NCT02487186 Phase 4 Doxicicline
44 EMD and/or Bone Substitute for the Treatment of Class II Furcations Completed NCT02474498 Phase 4 EMD
45 Effectiveness of Hygiene Solutions on Denture Biofilm Completed NCT02407834 Phase 4
46 Conventional or Minimally Invasive Surgical Technique for the Treatment of Furcation Defects Using Enamel Matrix Derivative and Anorganic Bovine Bone - a Randomized Controlled Clinical Trial. Completed NCT02102360 Phase 4
47 Pediatric Study to Access Pharmacokinetics and Safety of Oraqix Gel Completed NCT01591616 Phase 4 lidocaine and prilocaine
48 Photodynamic Therapy During Supportive Periodontal Therapy Completed NCT02666573 Phase 4
49 The Effects of Periodontal Therapy on Glycemic Control in Diabetic Patients Completed NCT03783845 Phase 4 amoxicillin and metronidazole
50 "Efficacy Of 1.2% Rosuvastatin Gel In The Management Of Infrabony Defects" Completed NCT03677297 Phase 4 Rosuvastatin

Search NIH Clinical Center for Mouth Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: mouth diseases

Genetic Tests for Mouth Disease

Genetic tests related to Mouth Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Mouth 30

Anatomical Context for Mouth Disease

MalaCards organs/tissues related to Mouth Disease:

42
Bone, Salivary Gland, Eye, Testes, Tongue, Kidney, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Mouth Disease:

20
The Mouth

Publications for Mouth Disease

Articles related to Mouth Disease:

(show top 50) (show all 3086)
# Title Authors Year
1
A case report of a teenager with severe hand, foot, and mouth disease with brainstem encephalitis caused by enterovirus 71. ( 30760232 )
2019
2
Time-series modelling and forecasting of hand, foot and mouth disease cases in China from 2008 to 2018. ( 30868999 )
2019
3
Enterovirus A71 Phenotypes Causing Hand, Foot and Mouth Disease, Vietnam. ( 30882309 )
2019
4
Spatiotemporal decomposition and risk determinants of hand, foot and mouth disease in Henan, China. ( 30550914 )
2019
5
Longitudinal study on enterovirus A71 and coxsackievirus A16 genotype/subgenotype replacements in hand, foot and mouth disease patients in Thailand, 2000-2017. ( 30639624 )
2019
6
The Effectiveness of Different Doses of Intravenous Immunoglobulin on Severe Hand, Foot and Mouth Disease: A Meta-Analysis. ( 30646003 )
2019
7
Low frequency, weak MCP-1 secretion and exhausted immune status of peripheral monocytes were associated with progression of severe enterovirus A71-infected hand, foot, and mouth disease. ( 30697697 )
2019
8
Prenatal exposure to perfluoroalkyl substances is associated with lower hand, foot and mouth disease viruses antibody response in infancy: Findings from the Guangzhou Birth Cohort Study. ( 30708217 )
2019
9
Analysis of the effect of PM10 on hand, foot and mouth disease in a basin terrain city. ( 30824722 )
2019
10
Epidemiologic features of enterovirus associated with hand, foot and mouth disease in 2013 and 2014 in Shenzhen, China. ( 30846756 )
2019
11
Hand, foot and mouth disease caused by Coxsackie viruses A6 and A16 in Assam, Northeast India: A need for surveillance. ( 30860171 )
2019
12
Near-Complete Genome Sequences of 12 Coxsackievirus Group A Strains from Hand, Foot, and Mouth Disease and Herpangina Cases with Different Clinical Symptoms. ( 30834371 )
2019
13
Remaining challenges for prevention and control of hand, foot, and mouth disease. ( 30885695 )
2019
14
Reconstructing foot-and-mouth disease outbreaks: a methods comparison of transmission network models. ( 30886211 )
2019
15
Immunogenicity and protective efficacy of recombinant proteins consisting of multiple epitopes of foot-and-mouth disease virus fused with flagellin. ( 30888465 )
2019
16
Foot-and-mouth disease vaccines: recent updates and future perspectives. ( 30888563 )
2019
17
Foot-and-mouth disease virus antagonizes NOD2-mediated antiviral effects by inhibition of NOD2 protein expression. ( 30894473 )
2019
18
Serological and molecular epidemiology of foot-and-mouth disease viruses in agro-pastoralist livestock herds in the Kachia Grazing Reserve, Nigeria. ( 30901506 )
2019
19
Identification of a conserved linear epitope using monoclonal antibody against non-structural protein 3A of foot-and-mouth disease virus with potential for differentiation between infected and vaccinated animals. ( 30904721 )
2019
20
Adjuvanticity of aqueous extracts of Artemisia rupestris L. for inactivated foot-and-mouth disease vaccine in mice. ( 30913435 )
2019
21
Assessing the spread of foot and mouth disease in mainland China by dynamical switching model. ( 30273575 )
2019
22
Serotyping of foot-and-mouth disease virus using oxford nanopore sequencing. ( 30393148 )
2019
23
A novel type I interferon, interferon alphaomega, shows antiviral activity against foot-and-mouth disease virus in vitro. ( 30500407 )
2019
24
Potent neutralization activity against type O foot-and-mouth disease virus elicited by a conserved type O neutralizing epitope displayed on bovine parvovirus virus-like particles. ( 30547855 )
2019
25
Short-term exposure to sulfur dioxide and the risk of childhood hand, foot, and mouth disease during different seasons in Hefei, China. ( 30577010 )
2019
26
Correction for Gladue et al., "Foot-and-Mouth Disease Virus Modulates Cellular Vimentin for Virus Survival". ( 30610111 )
2019
27
Ongoing change of severe hand, foot and mouth disease pathogens in Yunnan, China, 2012-2016. ( 30613995 )
2019
28
Epidemic pattern of hand-foot-and-mouth disease in Xi'an, China from 2008 through 2015. ( 30616531 )
2019
29
Proteogenomics Uncovers Critical Elements of Host Response in Bovine Soft Palate Epithelial Cells Following In Vitro Infection with Foot-And-Mouth Disease Virus. ( 30642035 )
2019
30
Chimeric vaccine strain of type O foot-and-mouth disease elicits a strong immune response in pigs against ME-SA and SEA topotypes. ( 30642587 )
2019
31
The effect of temperature, farm density and foot-and-mouth disease restrictions on the 2007 UK bluetongue outbreak. ( 30643158 )
2019
32
Advances in novel vaccines for foot and mouth disease: focus on recombinant empty capsids. ( 30654663 )
2019
33
Deciphering Foot-and-Mouth Disease (FMD) virus-host Tropism. ( 30654708 )
2019
34
Possible long-term sequelae in hand, foot, and mouth disease caused by Coxsackievirus A6. ( 30661911 )
2019
35
Surveillance for severe hand, foot, and mouth disease from 2009 to 2015 in Jiangsu province: epidemiology, etiology, and disease burden. ( 30669973 )
2019
36
Oral pre-administration of Purslane polysaccharides enhance immune responses to inactivated foot-and-mouth disease vaccine in mice. ( 30683105 )
2019
37
Considerations for design and implementation of vaccine field trials for novel foot-and-mouth disease vaccines. ( 30685245 )
2019
38
Genome Sequences of Antigenically Distinct Serotype O Foot-and-Mouth Disease Viruses from Pakistan. ( 30687826 )
2019
39
Engineering Responses to Amino Acid Substitutions in the VP0 and VP3 Coding Regions of PanAsia-1 Strains of Foot-and-Mouth Disease Virus Serotype O. ( 30700601 )
2019
40
Hollow Mesoporous Silica Nanoparticles as Delivery Vehicle of Foot-and-Mouth Disease Virus-like Particles Induce Persistent Immune Responses in Guinea Pigs. ( 30701562 )
2019
41
Effect of foot-and-mouth disease virus 3C protease B2 β-strand proline mutagenesis on expression and processing of the P1 polypeptide using a plasmid expression vector. ( 30702422 )
2019
42
Profiles of Human Enteroviruses Associated with Hand, Foot, and Mouth Disease in Nanjing, China. ( 30704549 )
2019
43
Response to comment on "First detection of foot-and-mouth disease virus O/ME-SA/Ind2001 in China". ( 30707501 )
2019
44
Letter to the editor about the classification of recently emerged foot-and-mouth disease virus O/ME-SA/Ind2001 sublineages concerning two published articles in Transboundary and Emerging Diseases. ( 30707504 )
2019
45
The pseudoknots region of the 5' untranslated region is a determinant of viral tropism and virulence of foot-and-mouth disease virus. ( 30728251 )
2019
46
Application of a combined model with seasonal autoregressive integrated moving average and support vector regression in forecasting hand-foot-mouth disease incidence in Wuhan, China. ( 30732135 )
2019
47
A framework for reviewing livestock disease reporting systems in high-risk areas: assessing performance and perceptions towards FMD reporting in the Thrace Region of Greece, Bulgaria and Turkey. ( 30734513 )
2019
48
Opportunities for enhanced surveillance of foot-and-mouth disease in endemic settings using milk samples. ( 30740915 )
2019
49
Complete Genome Sequence of O/VN1/2014, a Foot-and-Mouth Disease Virus of Serotype O Isolated in Vietnam in 2014. ( 30746514 )
2019
50
Short-term effects of extreme meteorological factors on childhood hand, foot, and mouth disease reinfection in Hefei, China: A distributed lag non-linear analysis. ( 30759610 )
2019

Variations for Mouth Disease

Expression for Mouth Disease

Search GEO for disease gene expression data for Mouth Disease.

Pathways for Mouth Disease